On Wednesday, Alaska Air Group, Inc. (NYSE:ALK)’s shares declined -0.47% to $66.19.
SkyWest Airlines declared that they will purchase eight new, dual-class Embraer E175 jets to fly for Alaska Airlines. The new planes, to be delivered in 2016, will replace eight older regional jets SkyWest presently flies for the Seattle-based carrier.
The declarement comes the same month SkyWest takes ownership of the first of seven E175s purchased last fall to be flown for Alaska under a capacity purchase agreement (CPA). The regional carrier will start flying the planes for Alaska on July 1 with the start of new service from Seattle to both Milwaukee and Oklahoma City, and between Portland, Oregon and St. Louis.
Alaska Air Group, Inc., through its auxiliaries, provides passengers and cargo air transportation services primarily in the United States. The company operates through Alaska Mainline and Alaska Regional segments. It serves about 100 cities in Alaska, the Lower 48, Hawaii, Canada, and Mexico. As of December 31, 2014, the company’s fleet comprised of 137 Boeing 737 jet aircraft; and 51 Bombardier Q400 turboprop aircraft. The company was founded in 1932 and is based in Seattle, Washington.
PMC-Sierra Inc (NASDAQ:PMCS)’s shares dropped -0.59% to $9.18.
PMC-Sierra Inc (PMCS) declared the appointment of Edward Sharp as chief strategy and technology officer. He reports to Greg Lang, PMC president and chief executive officer.
In this role, Sharp is responsible for leading PMC’s worldwide strategy and technology efforts, mapping emerging technologies into solutions that shape how the world consumes data. The exploding growth of big data puts PMC in a strong position to capitalize on the convergence of storage and networking, and to guide future industry-wide developments by participating in standards organizations.
Prior to joining PMC, Mr. Sharp was vice president of NetApp’s Emerging Products Group. He served in a number of roles of increasing scope in NetApp’s marketing, sales and product organizations from 1998 to 2014. Before joining NetApp, Mr. Sharp held positions at McKinsey & Company in the United States and the United Kingdom. He holds a Master of Science in Electrical Engineering from Stanford University and a Bachelor of Arts in Engineering, Economics and Administration from Oxford University.
PMC-Sierra, Inc. designs, develops, markets, and supports semiconductor solutions for communications network infrastructure equipment worldwide. Its semiconductor devices enable networking equipment primarily in three markets, counting storage, optical, and mobile networks.
At the end of Wednesday’s trade, Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD)‘s shares dipped -0.74% to $12.02.
Ironwood Pharmaceuticals, Inc. (IRWD) declared the pricing of $300 million aggregate principal amount of convertible senior unsecured notes that will mature on June 15, 2022 (the Notes). The Notes are being offered and sold to qualified institutional buyers following Rule 144A under the Securities Act of 1933, as amended. Ironwood has also granted the initial purchasers of the Notes an option to purchase up to an additional $45 million aggregate principal amount of the Notes solely to cover over-allotments.
The Notes will bear cash interest at a rate of 2.25%, payable on June 15 and December 15 of each year, startning on December 15, 2015. The Notes will not be redeemable prior to maturity. The Notes will be convertible, only during certain periods and subject to certain circumstances, into cash, shares of Ironwood Class A common stock, or a combination of cash and shares of Ironwood’s Class A common stock, at Ironwood’s election. The initial conversion rate for the Notes is 60.3209 shares of Ironwood’s Class A common stock per $1,000 principal amount of the Notes, which is equivalent to an initial conversion price of about $16.58 per share of Ironwood’s Class A common stock, representing an about 35% conversion premium based on the last stated sale price of Ironwood’s Class A common stock of $12.28 per share on June 9, 2015.
Ironwood Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, and commercialization of human therapeutic products. The company markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adult men and women suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Constella name in the European Union. It has partnershipagreements with Actavis plc and AstraZeneca AB to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other GI conditions in North America, in addition to in China, Hong Kong, and Macau.
TherapeuticsMD Inc (NYSEMKT:TXMD), ended its Wednesday’s trading session with 0.25% gain, and closed at $8.00.
TherapeuticsMD Inc (TXMD) declared that the Company has accomplished patient enrollment in The Rejoice Trial, a phase 3 clinical trial of TX-004HR (estradiol in VagiCap™) to evaluate multiple doses of an investigational, applicator-free vaginal estradiol for the treatment of pain during sexual intercourse (dyspareunia), a symptom of vulvar and vaginal atrophy (VVA), due to menopause.
TX-004HR is an investigational bio-identical estradiol softgel capsule administered vaginally without the need for an applicator. The Rejoice Trial is also collecting efficacy data on vaginal dryness, and vaginal and/or vulvar itching or burning.
TherapeuticsMD, Inc. operates as a woman’s health care product company. The company manufactures and distributes prescription and over-the-counter product lines, counting prenatal vitamins, iron supplements, vitamin D supplements, and natural menopause relief products under the vitaMedMD brand, in addition to duplicate formulations of its prescription prenatal vitamins products under the BocaGreenMD Prena1 name.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
